{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:35:34Z","timestamp":1761060934750,"version":"build-2065373602"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015003","name":"ACT","doi-asserted-by":"publisher","award":["NCT01994889"],"award-info":[{"award-number":["NCT01994889"]}],"id":[{"id":"10.13039\/100015003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015003","name":"ACT","doi-asserted-by":"publisher","award":["NCT02319005"],"award-info":[{"award-number":["NCT02319005"]}],"id":[{"id":"10.13039\/100015003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cjca.2019.12.015","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:43:52Z","timestamp":1576611832000},"page":"373-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic"],"prefix":"10.1016","volume":"36","author":[{"given":"Bennett","family":"Di Giovanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-6331","authenticated-orcid":false,"given":"Dakota","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell B.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego H.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.12.015_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4161\/pri.2.3.7488","article-title":"Amyloid fibrils: abnormal protein assembly","volume":"2","author":"Rambaran","year":"2008","journal-title":"Prion"},{"key":"10.1016\/j.cjca.2019.12.015_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.015_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjca.2019.12.015_bib6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jmb.2012.01.024","article-title":"A\u00a0molecular history of the amyloidoses","volume":"421","author":"Buxbaum","year":"2012","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.cjca.2019.12.015_bib8","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.015_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/CS20160413","article-title":"Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy","volume":"131","author":"Galant","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cjca.2019.12.015_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/CIRCULATIONAHA.117.027551","article-title":"Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance","volume":"138","author":"Chang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.015_bib11","first-page":"10","article-title":"National differences in trends for heart failure hospitalizations by sex and race\/ethnicity","author":"Ziaeian","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2019.12.015_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2019.12.015_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib14","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.015_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmg.2017.08.007","article-title":"Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades","volume":"11","author":"Vasan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2019.12.015_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092322","article-title":"Inflammatory and molecular pathways in heart failure\u2014ischemia, HFpEF and transthyretin cardiac amyloidosis","volume":"20","author":"Michels da Silva","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2019.12.015_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006169","article-title":"Cardiac amyloidosis a rare disease in older adults hospitalized for heart failure?","volume":"12","author":"Griffin","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2019.12.015_bib18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCRESAHA.117.310982","article-title":"Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Muchtar","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2019.12.015_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cjca.2019.12.015_bib22","first-page":"12","article-title":"Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy","volume":"75","author":"Ochi","year":"2020","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.12.015_bib24","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.015_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13156","article-title":"Guidelines on the diagnosis and investigation of AL amyloidosis","volume":"168","author":"Gillmore","year":"2015","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.cjca.2019.12.015_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management","volume":"6","author":"Real de","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib27","first-page":"770","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.12.015_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008148","article-title":"Apolipoprotein A-1\u2013related amyloidosis: 2 case reports and review of the literature","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2019.12.015_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2353\/jmoldx.2009.080161","article-title":"Hereditary apolipoprotein AI\u2013associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene","volume":"11","author":"Eriksson","year":"2009","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.cjca.2019.12.015_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4081\/itjm.2019.1149","article-title":"Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians","volume":"13","author":"Angelini","year":"2019","journal-title":"Ital J Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis. THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2019.12.015_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4065\/mcp.2009.0547","article-title":"Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cjca.2019.12.015_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","volume":"2012","author":"Merlini","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cjca.2019.12.015_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"10.1016\/j.cjca.2019.12.015_bib36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.cjca.2019.12.015_bib37","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in E ngland: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjca.2019.12.015_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cjca.2019.12.015_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.12.015_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/humu.23669","article-title":"Analysis of the TTR gene in the investigation of amyloidosis: a 25-year single UK center experience","volume":"40","author":"Rowczenio","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cjca.2019.12.015_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9440(10)65268-6","article-title":"Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1","volume":"154","author":"Hamidi Asl","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cjca.2019.12.015_bib42","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.cjca.2019.12.015_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13023-016-0564-2","article-title":"The burden of amyloid light chain amyloidosis on health-related quality of life","volume":"12","author":"Bayliss","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2019.12.015_bib44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review","volume":"33","author":"Lin","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2019.12.015_bib45","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"10.1016\/j.cjca.2019.12.015_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clml.2015.11.001","article-title":"Clinical characteristics and treatment outcome of Chinese patients with systemic amyloid light-chain amyloidosis: a retrospective single-center analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cjca.2019.12.015_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443200","article-title":"Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy","volume":"135","author":"Muchtar","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cjca.2019.12.015_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13506129.2011.560217","article-title":"Macroglossia\u2014not always AL amyloidosis","volume":"18","author":"Cowan","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib50","first-page":"71","article-title":"Cardiac amyloidosis and its new clinical phenotype: heart failure with preserved ejection fraction","volume":"109","author":"Mesquita","year":"2017","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cjca.2019.12.015_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506129.2011.571319","article-title":"Myocardial infarction with \u201cclean coronaries\u201d caused by amyloid light-chain AL amyloidosis: a case report and literature review","volume":"18","author":"Tsai","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2019.12.015_bib54","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2019.12.015_bib55","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrcardio.2014.165","article-title":"Pathophysiology and treatment of cardiac amyloidosis","volume":"12","author":"Gertz","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cjca.2019.12.015_bib57","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.ajpath.2011.06.024","article-title":"Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I","volume":"179","author":"Rowczenio","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cjca.2019.12.015_bib58","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes","year":"2016","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.cjca.2019.12.015_bib59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS\u2014the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cjca.2019.12.015_bib60","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.cjca.2019.12.015_bib61","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cjca.2019.12.015_bib62","doi-asserted-by":"crossref","first-page":"E6428","DOI":"10.1073\/pnas.1802977115","article-title":"Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease","volume":"115","author":"Klimtchuk","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2019.12.015_bib63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman","year":"2008","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib64","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib67","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","author":"Lahuerta Pueyo","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.cjca.2019.12.015_bib68","first-page":"9","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2019.12.015_bib69","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-019-08609-z","article-title":"A\u00a0molecular mechanism for transthyretin amyloidogenesis","volume":"10","author":"Yee","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2019.12.015_bib70","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2019.12.015_bib71","first-page":"189","article-title":"Clinical presentation, diagnosis and treatment of TTR amyloidosis","volume":"6","author":"Kapoor","year":"2019","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.cjca.2019.12.015_bib72","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.21037\/jtd.2018.03.134","article-title":"Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies","volume":"10","author":"Halatchev","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cjca.2019.12.015_bib73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506120600877136","article-title":"Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: toward tailoring of therapeutic strategies?","volume":"13","author":"Rapezzi","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib74","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","article-title":"A\u00a0study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK","volume":"87","author":"Carr","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cjca.2019.12.015_bib75","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3899\/jrheum.101362","article-title":"Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium","volume":"38","author":"Migita","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"8292","key":"10.1016\/j.cjca.2019.12.015_bib76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(82)90321-X","article-title":"Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis","volume":"2","author":"de Beer","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.12.015_bib77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib78","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbrc.2014.01.029","article-title":"Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties","volume":"444","author":"Takase","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2019.12.015_bib79","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1074\/jbc.M112.394155","article-title":"Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic nonpathogenic SAA2.2","volume":"288","author":"Srinivasan","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cjca.2019.12.015_bib80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/13506120308995250","article-title":"An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians","volume":"10","author":"Yamada","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/13506120902879905","article-title":"AA amyloidosis associated with a mutated serum amyloid A4 protein","volume":"16","author":"Murphy","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.rce.2012.09.001","article-title":"Clinical characteristics of patients with systemic amyloidosis from 2000-2010","volume":"213","author":"Real de As\u00faa","year":"2013","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.cjca.2019.12.015_bib83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/rheumatology\/35.1.44","article-title":"Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy","volume":"35","author":"Kobayashi","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.cjca.2019.12.015_bib84","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/add.14257","article-title":"Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs","volume":"113","author":"Harris","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.cjca.2019.12.015_bib85","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib86","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000489297","article-title":"Gastroparesis in a patient with gastric AL amyloidosis","volume":"12","author":"Hoscheit","year":"2018","journal-title":"Case Rep Gastroenterol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2019.12.015_bib87","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13506129.2011.574354085","article-title":"The changing face of AA amyloidosis: a single center experience","volume":"18","author":"Girnius","year":"2011","journal-title":"Amyloid"},{"key":"10.1016\/j.cjca.2019.12.015_bib88","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199 patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11255-009-9524-2","article-title":"Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre","volume":"41","author":"Poty\u0161ov\u00e1","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.cjca.2019.12.015_bib90","first-page":"213","article-title":"Ten years\u2019 experience of an amyloid clinic\u2014a clinicopathological survey","volume":"54","author":"Browning","year":"1985","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.cjca.2019.12.015_bib91","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1006\/bbrc.1999.0518","article-title":"A\u00a0novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis","volume":"257","author":"Asl","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2019.12.015_bib92","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0002-9440(10)65167-X","article-title":"The new apolipoprotein A-I variant Leu(174)--> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide","volume":"155","author":"Obici","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cjca.2019.12.015_bib93","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/labinvest.3700124","article-title":"Two different types of amyloid deposits\u2014apolipoprotein A-IV and transthyretin\u2014in a patient with systemic amyloidosis","volume":"84","author":"Bergstr\u00f6m","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.cjca.2019.12.015_bib94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.febslet.2013.10.049","article-title":"An N-terminal pro\u2013atrial natriuretic peptide (NT-proANP) \u201caggregation-prone\u201d segment involved in isolated atrial amyloidosis","volume":"588","author":"Louros","year":"2014","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cjca.2019.12.015_bib95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.carpath.2006.01.005","article-title":"Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy","volume":"15","author":"Steiner","year":"2006","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cjca.2019.12.015_bib96","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000177950","article-title":"The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens","volume":"113","author":"Ariyarajah","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2019.12.015_bib97","doi-asserted-by":"crossref","first-page":"293863","DOI":"10.1100\/2012\/293863","article-title":"Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure","volume":"2012","author":"Millucci","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.cjca.2019.12.015_bib98","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ehj.2004.04.007","article-title":"Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation","volume":"25","author":"Leone","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.12.015_bib99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1440-1827.1995.tb03466.x","article-title":"Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts","volume":"45","author":"Kawamura","year":"1995","journal-title":"Pathol Int"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19315284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19315284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:49Z","timestamp":1760107369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X19315284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0828282X19315284"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.12.015","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}